VIDEO: Vabysmo prefilled syringe offers potent, durable treatment option for RVO
KOLOA, Hawaii — In this expert perspective from Hawaiian Eye 2025, Ashkan M. Abbey, MD, discusses an advancement in retinal vein occlusion treatment from 2024 and highlights a treatment in the pipeline for 2025.
Abbey said the approval of the Vabysmo prefilled syringe (faricimab, Genentech) for the treatment of retinal vein occlusion (RVO) added durability to some patients’ treatment. Faricimab is another option for RVO instead of adding a steroid to aflibercept or bevacizumab.
“Looking forward to 2025 now, we may have another great potent, durable anti-VEGF option coming out, which would be high-dose aflibercept,” Abbey said. “That hopefully will have its indication to occur this year and approved by the FDA for this year, so that we will have another tool in our toolbox to attack macular edema associated with retinal vein occlusion, which continues to be kind of a challenging disease to control.”
Collapse
Read more about